142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

Adding to the HIV Prevention Toolkit: High Interest in a Long-Acting Injectable Formulation of Pre-Exposure Prophylaxis in a Cohort of Young Men who have Sex with Men in NYC

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Wednesday, November 19, 2014 : 10:45 AM - 11:00 AM

Kristina Rodriguez, MPH , Aaron Diamond AIDS Research Center, New York, NY
Kathrine Meyers, DrPH MPP , Aaron Diamond AIDS Research Center, New York, NY
Robert W. Moeller, EdM , Center for Health, Identity, Behavior & Prevention Studies, Steinhardt School of Culture, Education, and Human Development, New York University, New York, NY
Ilana Gratch , Middlebury University
Marty Markowitz, MD , Aaron Diamond AIDS Research Center, New York, NY
Perry N. Halkitis, PhD, MPH , Global Institute of Public Health, New York University, New York, NY
Background:  In the context of continued high rates of HIV-1 infection, particularly in high-risk populations such as young MSM(YMSM) of color, additional effective and desirable HIV prevention tools are needed.  The efficacy of daily oral PrEP has ranged widely across clinical trials due to variable adherence. Long-acting injectable PrEP(LAI-PrEP) could circumvent adherence challenges, however, desirability and acceptability of such an agent has not yet been assessed among target populations in the US.

Methods:  Between May-August 2013, a cross-sectional study was conducted with a racially/ethnically diverse cohort of YMSM in NYC. Three outcome measures were assessed: 1) willingness to use LAI-P; 2) preference for route of administration; and 3) major concerns with LAI-PrEP.  

Results:  Of 197 YMSM (74.1% of color), 80% responded that they would definitely/probably try LAI-P and 85.7% preferred injection every three months over daily oral administration. No difference in interest and preference was seen across groups by race/ethnicity, socioeconomic status, education, or risk behavior. Major concerns around LAI-P were side effects (87.8%,n=173), long-term health effects (85.8%,n=169) and uncertainty of drug’s effectiveness (83.3%,n=164). In addition, personal concerns such as risk disinhibition and stigma were noted: 47.2% stated they might be more likely to reduce their condom use if taking PrEP and 28.4% worried they would be mistaken as HIV-infected.

Conclusions:  This study is the first to explore acceptability of LAI-P in the US. The significant preference for LAI-P over daily oral PrEP across all groups suggests that a LAI product would be a welcome addition to the prevention toolkit.

Learning Areas:

Basic medical science applied in public health
Clinical medicine applied in public health
Implementation of health education strategies, interventions and programs
Public health or related education
Social and behavioral sciences

Learning Objectives:
Compare the acceptability of long-acting injectable PrEP to daily oral PrEP in a racially and ethnically diverse cohort of young men who have sex with men.

Keyword(s): HIV/AIDS, Prevention

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have participated in various quantitative clinical research projects addressing issues of HIV-1 pathogenesis and treatment. Recently, I have been co-investigator in a mixed methods research project investigating attitudes towards and behavioral correlates of interest in long-acting PrEP among MSM. In addition, I am a doctoral student at the CUNY graduate center.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.